FBMKLCI
1809.39 +1.52pts (+0.08%) Volume
2.470b Value 1.836b
1) The KLCI closed flat today despite the U.S market which soared to record
highs on Friday after Greek and EU zone finance ministers reached a deal to
extend Greece's bailout plans. In the regional market, bourses were generally
positive today as investors await progress on Greece's reforms later today;
SHCOMP +0.76% led the major bourses in gains as it prepares to introduce short
selling to the SH-HK link next month, NIKKEI +0.73% climbed to 15 year highs on
optimism while the HSI +0.02% remained flat for the day. In the local scene,
ACE market names flood the market with liquidity as TMS +8.33%, ASIABIO
+12.00%, RA 0.00%, DGSB +30.00%, WINTONI +6.25% tops the list of the most
active. Market breadth was positive with gainers outpacing losers by 428 : 382.
Futures closed at 1810 (1pt premium).
2) Heavyweights : CIMB +1.35% RM5.98, PCHEM +2.22% RM5.51, MAXIS +1.69% RM7.20,
GENTING +1.15% RM8.76, PETGAS +1.07% RM22.54, MAYBANK -2.06% RM9.03, SKPETRO
-1.67% RM2.94, BAT -1.89% RM 69.38.
3) DBT: SEM 35.958mil @ RM1.50 (2.91% PUC), REX 11.21mil @ RM1.40 (19.99% PUC),
BJAUTO 10.4mil @ RM3.23 (1.27% PUC @ 8.8% PUC).
4) Situational:-
EATECH -4.83% RM0.59 - E.A. Technique (M) Bhd has been awarded a US$191.8
million (RM687.1 million) job for the provision of engineering, procurement,
construction, transportation, installation and commissioning (EPCIC) contract
for the North Malay Basin project. In a filing with Bursa Malaysia yesterday,
the group said the contract, covers work on EPCIC of a floating storage and
offloading (FSO) facility for Full Field Development (FFD) project. The
contract is effective for 20 months, with work commencing on Dec 22, 2014 until
Aug 22, 2016. E.A. Technique said the contract will have no effect on its
issued and paid-up capital, as well as shareholdings of its substantial
shareholders.
5) PHARMA : FY12/14 Rev+9% RM2.12b Net+12% RM93.8m EPS 36.5s
Div 28s
Results 12% ahead of Earnings cons RM83.5m, Dividend
cons 18.7s.
For 12 mths yoy, higher revenue was on the back of stronger contributions from
business operations. PBT was 35% higher, mainly contributed by steady growth in
revenue coupled with reduced operating expenses, including amortization and
provision of doubtful debts. Logistic & Distribution div - PBT +88% on the
back of higher revenue & lower provision of doubtful debts. In the
Manufacturing div, PBT +19% due to improved margins following an increase in
average selling price coupled with higher off-take for in house products from
government hospitals. Qoq, revenue was +25% while PBT +52% ( Logistic PBT+300%
due to higher demand from government hospitals while Manufacturing PBT was
flat). Group announced 4th interim dividend of 12s, above market expectations.
Ahead, the pharmaceutical sector in Malaysia continues to hold much potential
for growth opportunities. Group expect stronger contribution from the
manufacturing plant in Indonesia upon the completion of the acquisition and
streamlining of activities in the plant - We continue to like Pharma for its
defensive earnings being the sole concession holder to purchase, store,
supplies and distribute approved drugs and medical products to Government
hospitals and clinics nationwide, its growth exposure in the healthcare and
pharmaceuticals industry supported by an ageing population, and decent dividend
yield in excess of 4.5% - Accumulate.
6) Market : It is likely that foreign selling and local buying activities may
just about match off in the current market phase. Market likely to remain
relatively quiet this week after the CNY holidays. Trading range between
1780-1830 points.
